DVD-Ig Multivalent Antibody Homogeneous Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing bispecific antibodies face challenges such as molecular heterogeneity, reduced production yields, and increased immunogenicity due to the need for sophisticated purification procedures and mutational modifications, which affect their stability and efficacy.
Innovation Solution
The development of dual variable domain immunoglobulins (DVD-Ig) with a polypeptide chain structure comprising VD1-(X1)n-VD2-C-(X2)n, where VD1 and VD2 are variable domains capable of binding different or the same antigens, and X1 and X2 are linkers or Fc regions, allowing for high-affinity binding to multiple antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If quadroma technology is used to produce bisspecific antibodies, then bispecific binding capability is achieved, but molecular heterogeneity increases and production yield decreases
Solution Approach 1:
The patent divides the antibody structure into separate heavy and light chain domains that are independently expressed and then assemble. The heavy chain contains one variable domain (VH) and the light chain contains one variable domain (VL), with constant regions engineered to promote correct pairing. This segmentation allows controlled assembly into homogeneous bispecific antibodies rather than random pairing in quadroma cells.
Solution Approach 2:
The patent introduces specific local modifications to the constant regions (CH1 and CL domains) to create complementary properties that enforce correct pairing. The CH1 domain contains a cysteine residue at position 234 and the CL domain contains a cysteine at position 119, creating a disulfide bond that locks the correct heavy-light chain pairing. This local quality modification ensures molecular homogeneity while maintaining bispecific binding capability.
2Adaptability or versatility
If chemical conjugation methods are used to produce bisspecific antibodies, then binding capability is achieved, but molecular heterogeneity increases
Solution Approach 1:
The patent replaces chemical conjugation methods with a biological assembly system. Instead of using chemical crosslinkers to attach different antibody fragments (which creates heterogeneity due to random reaction sites), the invention uses recombinant DNA technology to express engineered heavy and light chains that self-assemble through programmed disulfide bonds and hydrophobic interactions in the constant regions. This mechanical/biological substitution achieves site-directed pairing with high homogeneity.
3Manufacturing precision
If sophisticated purification procedures are applied to remove mis-paired by-products, then molecular homogeneity is improved, but production yield decreases
Solution Approach 1:
The patent performs preliminary action by engineering the constant regions with predetermined pairing properties before expression. The CH1 and CL domains are designed with complementary cysteine residues and hydrophobic patches that pre-program correct heavy-light chain pairing. This preliminary structural design prevents mispairing from occurring in the first place, eliminating the need for sophisticated purification procedures and maximizing production yield while maintaining homogeneity.
4Stability of the object's composition
If mutational modifications are introduced to improve antibody stability, then stability is enhanced, but immunogenicity increases
Solution Approach 1:
The patent makes controlled parameter changes by introducing specific mutations in the constant regions (CH1 and CL domains) to improve stability through enhanced disulfide bonding and hydrophobic interactions. The mutations are strategically placed in non-CDR regions to maintain antigen binding specificity while improving structural stability. By carefully selecting mutations that affect stability parameters without altering antigen-binding properties, the patent minimizes immunogenicity while enhancing stability.
Data Source
AI summary
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.